Supernus Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results

Published: Mar 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., March 12, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today reported financial results for the fourth quarter and full year 2013 and discussed key company developments. "We are very pleased with the continued progress of our business, as evidenced by very strong quarter to quarter prescription growth. Prescriptions filled at the pharmacy level in the fourth quarter of 2013 increased by 12,527, or more than 100%, as compared to the third quarter," said Jack Khattar, President and CEO of Supernus Pharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news